Skip to main content
Equibles
ARMP logo

ARMP · Armata Pharmaceuticals, Inc.

Track ARMP — free

Use ARMP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ARMP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.56 -0.26 (-5.39%) At close · Aug 14
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within our control and cannot be assessed as being probable of occurring.”
View the 10-Q filed Aug 12, 2026
Market Cap
$169.55M
Shares
37.18M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.56 Open$4.79 Day$4.40–4.93 52W close$2.43–14.80 Avg vol 30d158K Short int856K · 2.3% float · 5.0d Short vol58% Last earningsNov 25, 2025 DataJan 2020–Aug 2026 Filing10-Q · Aug 12

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −40%
below
Price vs 50-day avg −19%
below
RSI (14) 44
neutral
MACD trend Positive
52-week position 17%
mid-range
Momentum
relative strength
Very Weak
1-month return +1%
trailing
6-month return −52%
trailing
YTD return −27%
this year
Relative strength −66%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+18% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.30% of float · ▲ +21.5% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
53 holders — near 3-yr high, broad support
Squeeze score 55
elevated · 0–100
Fundamentals
Weak
EPS growth −439%
Y/Y
Free cash flow $-26.3M
Balance sheet $8.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 148%
annualized · 1-yr
Max drawdown −75%
past year
ATR 12.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−40% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
44 Neutral
MACD trend
Positive Bullish
52-week position
17% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+18% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.30% of float · ▲ +21.5% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
53 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $5 · 17% Range high $15
vs 200-day avg -40% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ARMP
Armata Pharmaceuticals, Inc.
this stock
$169.55M -27.4% — — 2.3%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
53
% held
13.4%
Net QoQ
+1.1M sh
Top holder
Madison Asset Management,…
Held Float
View
Held by Funds
Fund positions
14
View
Short & Settlement
Short Interest Rising
Shares short
856.4K
Days to cover
5.0d
Change
+151.7K sh
View
Short Volume
Short vol %
58%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$7.3K
As of
Jul 2, 2026
View
Off-Exchange
Off-exchange %
31.6%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-173.8M
EPS diluted
$-4.80
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
20
View
Earnings & Events
Earnings Calls
Last call
Nov 25, 2025
View

Performance

5D 20D 120D MTD YTD
ARMP -3.2% +1.1% -52.2% +0.4% -27.4%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -3.6% -3.3% -66.0% -3.5% -41.2%
Key facts CIK 921114 CUSIP 04216R102 13F (30d) 51 filings 51 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)